Trevi Therapeutics(US:TRVI) Prnewswire·2024-08-01 11:30Company Overview - Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing Haduvio™ (oral nalbuphine ER) for treating chronic cough associated with idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) [3] - Haduvio acts as a dual κ-opioid receptor agonist and µ-opioid receptor antagonist, potentially providing a synergistic antitussive effect [3] Market Opportunity - Chronic cough significantly impacts patients' social, physical, and psychological quality of life, particularly in IPF, where it may worsen the disease and increase risks of progression, death, or lung transplant [4] - Current treatment options for chronic cough in IPF offer minimal benefits, and there are no approved therapies for RCC in the US, indicating a substantial unmet medical need [4] Upcoming Events - The company will host a conference call and live audio webcast on August 8, 2024, at 4:30 p.m. ET to provide a corporate update and review financial results for the quarter ended June 30, 2024 [1][2]